159.35 +0.24 (0.15%)
After hours: 7:17PM EDT
|Bid||159.35 x 800|
|Ask||159.33 x 800|
|Day's range||159.04 - 161.19|
|52-week range||114.27 - 197.00|
|Beta (3Y monthly)||1.95|
|PE ratio (TTM)||N/A|
|Earnings date||28 Oct. 2019 - 1 Nov. 2019|
|Forward dividend & yield||2.96 (1.87%)|
|1y target est||181.38|
Allergan's (AGN) pending merger with AbbVie, positive pipeline and regulatory updates and increase in sales guidance twice are driving shares up this year.
Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...
Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.
(Bloomberg) -- As hedge fund holdings data pour in, investors will be keeping an eye on which managers may be exposed to the market apoplexy unfolding in Argentina.Managers including Autonomy Capital’s Robert Gibbins and Pointstate Capital’s Zach Schreiber started the year with bets on Argentine companies that trade in the U.S. After hedge funds finish reporting their end-of-June U.S. equity holdings Wednesday, investors will have an idea whether managers were adding to, or shedding, their positions in the nation during the months prior to the presidential primary elections held Sunday.President Mauricio Macri’s stunningly poor showing sent Argentina’s stocks, bonds and currency into a tailspin Monday as investors grappled with the idea that the market-friendly candidate will probably lose his re-election bid in October. They’re worried that opposition candidate Alberto Fernandez and his running mate, former president Cristina Fernandez de Kirchner, will bring back the protectionist policies that marked her administration.In an interview with Bloomberg in April, Gibbins, who manages about $5.5 billion, said he expected voters to ultimately elect a market-friendly candidate in October, even if it isn’t Macri.“Faced with the choice between going back to what they know to have failed, which was Cristina Kirchner, in kind of a profound de-institutionalization, I think that Argentines are going to choose to carry forward with the path -- whether it’s with Mauricio Macri, or with somebody else” from his party, Gibbins said.As of the end of March, Gibbins’s biggest publicly traded U.S. equity positions were in Argentine stocks, including mall operator IRSA Inversiones y Representaciones SA and banks Grupo Financiero Galicia SA and Banco Macro SA.Emerging markets, in general, have sold off as the rout in Argentina and escalating protests in Hong Kong spook investors already on edge over the trade war. As 13F filings come in, investors will also look to see who was exposed to the developing world, as well as these other themes:The so-called FAANG group of major technology and internet stocks. Google parent Alphabet Inc. suffered a big one-day drop in late April on the back of a disappointing earnings report, while Netflix Inc. in July reported disappointing subscriber numbers that sent shares falling.The underwhelming IPOs of the second quarter, including Uber Technologies Inc., and the eye-popping ones, like Beyond Meat Inc., Chewy Inc., Crowdstrike Holdings Inc. and Revolve Group Inc.Mergers and acquisitions, particularly AbbVie Inc.’s mega-deal to buy Botox maker Allergan Plc for $63 billion.Money managers who oversee more than $100 million in equities in the U.S. must file a Form 13F within 45 days of each quarter’s end to list those stocks as well as options and convertible bonds. The filings don’t show non-U.S. securities, holdings that aren’t publicly traded, or cash.To contact the reporters on this story: Katia Porzecanski in New York at firstname.lastname@example.org;Nishant Kumar in London at email@example.comTo contact the editors responsible for this story: Alan Mirabella at firstname.lastname@example.org, Josh Friedman, Dan ReichlFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.
JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.
Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.
In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.
Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.
Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Allergan (AGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vabomere and Minocin are expected to drive Melinta's (MLNT) second-quarter revenues. Operating expenses are likely to be lower. The company may provide update on progress of Baxdela label expansion.
Allergan (AGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Guardant Health (GH) will provide updates on Guardant360 and GuardantOMNI tests during the second-quarter 2019 earnings call.